Back to all bills
HR 3082119th CongressIn Committee
Evidence-Based Drug Policy Act of 2025
Introduced: Apr 29, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs
The Evidence-Based Drug Policy Act of 2025 is a narrowly targeted bill that would repeal a single existing provision, Section 704(b)(12), of the Office of National Drug Control Policy Reauthorization Act of 1998. By removing that provision, the bill does not create any new programs, funding, or authorities; it simply eliminates one preexisting requirement. The bill’s short title signals an intention to align drug policy with evidence-based approaches, but the text provides no new policy directives beyond the repeal. The exact practical effect depends on what Section 704(b)(12) mandated in 1998, which is not described in the bill’s language here.
Key Points
- 1The bill repeals Section 704(b)(12) of the Office of National Drug Control Policy Reauthorization Act of 1998 (21 U.S.C. 1703(b)(12)).
- 2It does not establish new programs, funding, or authorities; its action is strictly to remove an existing provision.
- 3The short title, “Evidence-Based Drug Policy Act of 2025,” suggests a focus on evidence-based policymaking, but no concrete evidence-based measures are added in the bill itself.
- 4Introduced in the House by Representatives Titus and Omar on April 29, 2025, and referred to the Committee on Oversight and Government Reform, as well as the Committees on Energy and Commerce and the Judiciary.
- 5The real-world impact depends on the content and role of the repealed Section 704(b)(12); removing it could reduce constraints or requirements tied to that provision, but the bill does not specify what changes in practice will occur.
Impact Areas
Primary: Office of National Drug Control Policy (ONDCP) and federal drug policy formulation, along with congressional oversight related to ONDCP activities.Secondary: Other federal agencies implementing ONDCP policies; researchers, policymakers, and advocacy groups interested in evidence-based approaches to drug policy.Additional impacts: Potential changes to reporting, evaluation, or statutory requirements tied to 704(b)(12); any downstream effects on accountability, transparency, or policy development processes may hinge on what the repealed provision actually required.
Generated by gpt-5-nano on Nov 19, 2025